Performance of some multiple testing procedures to compare three doses of a test drug and placebo

Lan Kong, Gary Koch, Thomas Liu, Huei Wang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A study design with two or more doses of a test drug and placebo is frequently used in clinical drug development. Multiplicity issues arise when there are multiple comparisons between doses of test drug and placebo, and also when there are comparisons of doses with one another. An appropriate analysis strategy needs to be specified in advance to avoid spurious results through insufficient control of Type I error, as well as to avoid the loss of power due to excessively conservative adjustments for multiplicity. For evaluation of alternative strategies with possibly complex management of multiplicity, we compare the performance of several testing procedures through the simulated data that represent various patterns of treatment differences. The purpose is to identify which methods perform better or more robustly than the others and under what conditions.

Original languageEnglish (US)
Pages (from-to)25-35
Number of pages11
JournalPharmaceutical Statistics
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Multiple Testing
Dose
Multiplicity
Drugs
Placebos
Pharmaceutical Preparations
Multiple Comparisons
Type I error
Adjustment
Testing
Alternatives
Evaluation
Strategy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Statistics and Probability
  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{bffb66cb5e484618bb3edcc592bcab96,
title = "Performance of some multiple testing procedures to compare three doses of a test drug and placebo",
abstract = "A study design with two or more doses of a test drug and placebo is frequently used in clinical drug development. Multiplicity issues arise when there are multiple comparisons between doses of test drug and placebo, and also when there are comparisons of doses with one another. An appropriate analysis strategy needs to be specified in advance to avoid spurious results through insufficient control of Type I error, as well as to avoid the loss of power due to excessively conservative adjustments for multiplicity. For evaluation of alternative strategies with possibly complex management of multiplicity, we compare the performance of several testing procedures through the simulated data that represent various patterns of treatment differences. The purpose is to identify which methods perform better or more robustly than the others and under what conditions.",
author = "Lan Kong and Gary Koch and Thomas Liu and Huei Wang",
year = "2005",
month = "1",
day = "1",
doi = "10.1002/pst.148",
language = "English (US)",
volume = "4",
pages = "25--35",
journal = "Pharmaceutical Statistics",
issn = "1539-1604",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

Performance of some multiple testing procedures to compare three doses of a test drug and placebo. / Kong, Lan; Koch, Gary; Liu, Thomas; Wang, Huei.

In: Pharmaceutical Statistics, Vol. 4, No. 1, 01.01.2005, p. 25-35.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Performance of some multiple testing procedures to compare three doses of a test drug and placebo

AU - Kong, Lan

AU - Koch, Gary

AU - Liu, Thomas

AU - Wang, Huei

PY - 2005/1/1

Y1 - 2005/1/1

N2 - A study design with two or more doses of a test drug and placebo is frequently used in clinical drug development. Multiplicity issues arise when there are multiple comparisons between doses of test drug and placebo, and also when there are comparisons of doses with one another. An appropriate analysis strategy needs to be specified in advance to avoid spurious results through insufficient control of Type I error, as well as to avoid the loss of power due to excessively conservative adjustments for multiplicity. For evaluation of alternative strategies with possibly complex management of multiplicity, we compare the performance of several testing procedures through the simulated data that represent various patterns of treatment differences. The purpose is to identify which methods perform better or more robustly than the others and under what conditions.

AB - A study design with two or more doses of a test drug and placebo is frequently used in clinical drug development. Multiplicity issues arise when there are multiple comparisons between doses of test drug and placebo, and also when there are comparisons of doses with one another. An appropriate analysis strategy needs to be specified in advance to avoid spurious results through insufficient control of Type I error, as well as to avoid the loss of power due to excessively conservative adjustments for multiplicity. For evaluation of alternative strategies with possibly complex management of multiplicity, we compare the performance of several testing procedures through the simulated data that represent various patterns of treatment differences. The purpose is to identify which methods perform better or more robustly than the others and under what conditions.

UR - http://www.scopus.com/inward/record.url?scp=15844389520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15844389520&partnerID=8YFLogxK

U2 - 10.1002/pst.148

DO - 10.1002/pst.148

M3 - Article

AN - SCOPUS:15844389520

VL - 4

SP - 25

EP - 35

JO - Pharmaceutical Statistics

JF - Pharmaceutical Statistics

SN - 1539-1604

IS - 1

ER -